Experimental drug could help treat inflammatory bowel disease. Many treatments fails to treat inflammatory bowel disease by targeting inflammation. Now new study found that restricting a protein from blood clotting could help relief symptoms.
The researchers studied genetic data of a number of people with inflammatory bowel disease (IBD). They found higher activity in genes which was associated with blood clotting in those who had severe symptoms. Scientists at the Washington University School of Medicine in St. Louis, MO conducted the study.
The researchers focused on the gene SERPINE-1 and PAI-1 which played a key role the early stages of blood clotting. They used IBD mice and treated them with an experimental drug called MDI-2268. They found that this drug blocked the action of PAI-1 and relieved the symptoms of IBD in a mouse model.
Prof. Stappenbeck explains, “We found a unique target that’s not an inflammatory molecule, and yet blocking it reduces inflammation and signs of disease, at least in mice.” He added “If further research bears out our findings, we think this target could be helpful to a greater number of patients.”
The symptoms of IBD includes diarrhea, abdominal pain, loss of weight, and fatigue.
Scientists say they hope that their finding will lead to new treatment approach for people who are suffering from IBD and getting no relief from current therapies. The new study research now features in the journal Science Translational Medicine.
“There’s a lot of interest in novel therapeutic approaches for IBD because inhibiting inflammatory molecules doesn’t work for all patients,” Prof. Stappenbeck said.